Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for treating diabetes, work by stimulating insulin secretion and suppressing glucagon release, thereby…
The Duchenne muscular dystrophy (DMD) landscape across the seven major markets (7MM) - the US, France, Germany, Italy, Spain, the…
US President Donald Trump kicked off his second term with a series of directives aimed at the US National Institutes…
The obesity market is growing at an unprecedented rate following the entrance of GLP-1 receptor agonists. In a recently published…
The pharmaceutical industry is bracing for potentially major disruptions following US President Donald Trump’s announcement of new tariffs on imported…
During the 43rd J.P. Morgan Annual Healthcare Conference last month, Areteia Therapeutics took centre stage, presenting a detailed review of…
The top 20 biopharmaceutical companies experienced mixed performance in 2024 amid a dynamic landscape influenced by US Federal Reserve interest…
In a groundbreaking application of data science, researchers have revisited the landmark Diabetes Control and Complications Trial (DCCT) by integrating…
Emergent Biosolutions (Gaithersburg, US) has purchased US and Canadian rights to Kloxxado, adding to its opioid overdose treatment portfolio, which…
Regulatory authorities play a pivotal role in accelerating, encouraging and incentivising the development and approval of novel treatments via the…
